PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Soleno Therapeutics, Inc. (SLNO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US8342032005

CUSIP

834203200

Sector

Healthcare

IPO Date

Nov 13, 2014

Highlights

Market Cap

$2.23B

EPS (TTM)

-$2.79

Total Revenue (TTM)

$3.45M

Gross Profit (TTM)

$1.97M

EBITDA (TTM)

-$136.50M

Year Range

$26.38 - $59.75

Target Price

$74.25

Short %

21.87%

Short Ratio

8.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
SLNO vs. ALAR SLNO vs. TRML SLNO vs. CBZ SLNO vs. RXST SLNO vs. SWVL SLNO vs. SPY SLNO vs. NVDA SLNO vs. COST SLNO vs. RIOT SLNO vs. PLTR
Popular comparisons:
SLNO vs. ALAR SLNO vs. TRML SLNO vs. CBZ SLNO vs. RXST SLNO vs. SWVL SLNO vs. SPY SLNO vs. NVDA SLNO vs. COST SLNO vs. RIOT SLNO vs. PLTR

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Soleno Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%30.00%40.00%JuneJulyAugustSeptemberOctoberNovember
32.74%
12.14%
SLNO (Soleno Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Soleno Therapeutics, Inc. had a return of 35.73% year-to-date (YTD) and 95.11% in the last 12 months. Over the past 10 years, Soleno Therapeutics, Inc. had an annualized return of -14.81%, while the S&P 500 had an annualized return of 11.16%, indicating that Soleno Therapeutics, Inc. did not perform as well as the benchmark.


SLNO

YTD

35.73%

1M

1.85%

6M

32.69%

1Y

95.11%

5Y (annualized)

18.68%

10Y (annualized)

-14.81%

^GSPC (Benchmark)

YTD

24.72%

1M

1.67%

6M

12.93%

1Y

30.55%

5Y (annualized)

13.88%

10Y (annualized)

11.16%

Monthly Returns

The table below presents the monthly returns of SLNO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202415.16%4.25%-11.42%4.35%-5.78%-3.04%18.21%1.49%3.15%9.05%35.73%
202346.97%-30.24%5.42%57.48%56.38%-18.60%18.88%-4.12%503.48%-19.18%24.78%35.25%1,932.83%
2022-13.41%-8.93%-31.02%-10.36%-19.31%14.63%-7.52%-14.23%-24.09%-40.72%9.09%83.33%-67.80%
20211.55%22.96%-47.72%-3.97%-14.88%10.68%-20.18%0.47%1.12%-19.55%-12.26%-37.17%-78.76%
202017.69%-19.65%-14.39%28.15%10.16%-33.93%-22.52%24.42%17.29%-30.68%12.64%-1.53%-34.35%
20193.51%-16.38%39.19%-2.43%46.77%-5.08%-21.43%-18.64%-16.20%2.00%13.07%69.94%71.93%
2018-1.66%-5.09%7.92%-8.44%25.60%12.23%15.81%-22.51%2.86%-3.24%-7.66%-11.40%-5.00%
20174.94%-23.53%9.23%-15.49%6.65%-21.71%-0.56%23.44%-15.45%-25.77%-24.35%23.29%-55.56%
2016-27.57%-14.18%3.39%2.61%9.02%-12.78%-18.97%9.57%-12.62%14.44%-8.74%-13.83%-56.22%
2015-10.83%373.68%1.59%-1.41%-31.06%-35.40%-22.06%5.48%-8.66%-12.80%8.70%-7.50%24.03%
2014-14.18%-55.21%-61.56%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of SLNO is 81, placing it in the top 19% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of SLNO is 8181
Combined Rank
The Sharpe Ratio Rank of SLNO is 8585
Sharpe Ratio Rank
The Sortino Ratio Rank of SLNO is 8282
Sortino Ratio Rank
The Omega Ratio Rank of SLNO is 7676
Omega Ratio Rank
The Calmar Ratio Rank of SLNO is 7676
Calmar Ratio Rank
The Martin Ratio Rank of SLNO is 8484
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Soleno Therapeutics, Inc. (SLNO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for SLNO, currently valued at 1.62, compared to the broader market-4.00-2.000.002.004.001.622.54
The chart of Sortino ratio for SLNO, currently valued at 2.34, compared to the broader market-4.00-2.000.002.004.002.343.40
The chart of Omega ratio for SLNO, currently valued at 1.27, compared to the broader market0.501.001.502.001.271.47
The chart of Calmar ratio for SLNO, currently valued at 1.00, compared to the broader market0.002.004.006.001.003.66
The chart of Martin ratio for SLNO, currently valued at 7.66, compared to the broader market0.0010.0020.0030.007.6616.26
SLNO
^GSPC

The current Soleno Therapeutics, Inc. Sharpe ratio is 1.62. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Soleno Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio1.001.502.002.503.003.50JuneJulyAugustSeptemberOctoberNovember
1.62
2.54
SLNO (Soleno Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Soleno Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-91.68%
-0.88%
SLNO (Soleno Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Soleno Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Soleno Therapeutics, Inc. was 99.86%, occurring on Dec 15, 2022. The portfolio has not yet recovered.

The current Soleno Therapeutics, Inc. drawdown is 91.68%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.86%Mar 5, 20151962Dec 15, 2022
-70.79%Nov 18, 201445Jan 27, 201515Feb 18, 201560
-9.74%Feb 27, 20151Feb 27, 20152Mar 3, 20153
-8.56%Feb 19, 20152Feb 20, 20151Feb 23, 20153
-8.35%Feb 25, 20151Feb 25, 20151Feb 26, 20152

Volatility

Volatility Chart

The current Soleno Therapeutics, Inc. volatility is 10.92%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%JuneJulyAugustSeptemberOctoberNovember
10.92%
3.96%
SLNO (Soleno Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Soleno Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Soleno Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items